Record Display for the EPA National Library Catalog

RECORD NUMBER: 30 OF 79

OLS Field Name OLS Field Data
Main Title Effects of Type I and II Pyrethroids on Motor Activity and the Acoustic Startle Response in the Rat (Journal Version).
Author Crofton, K. M. ; Reiter, L. W. ;
CORP Author Health Effects Research Lab., Research Triangle Park, NC. Neurotoxicology Div.
Publisher 1987
Year Published 1987
Report Number EPA/600/J-88/097;
Stock Number PB89-109292
Additional Subjects Insecticides ; Toxicity ; DDT ; Chlorine organic compounds ; Fluorine organic compounds ; Oxygen heterocyclic compounds ; Reprints ; Pryethrins ; Dose-response relationships ; CAS 50-29-3 ; CAS 52645-53-1 ; CAS 22431-62-5 ; CAS 68359-37-5 ; CAS 52315-07-8 ; CAS 51630-58-1 ; CAS 69409-94-5 ; CAS 70124-77-5 ; Motor activity ; Startle reaction
Holdings
Library Call Number Additional Info Location Last
Modified
Checkout
Status
NTIS  PB89-109292 Most EPA libraries have a fiche copy filed under the call number shown. Check with individual libraries about paper copy. NTIS 03/14/1989
Collation 13p
Abstract
Two behavioral tests, locomotor activity and the acoustic startle response (ASR), were utilized to separate the behavioral actions of Type I and II pyrethroids using permethrin, RU11679, cypermethrin, RU26607, fenvalerate, cyfluthrin, flucythrinate, fluvalinate and p,p'-DDT. Dosage-effect functions for all compounds were determined for both figure-8 maze activity and the ASR in the rat. All compounds were administered po in 1 ml/kg corn oil 1.5 - 3 hr prior to testing. The Type I compounds permethrin RU11679, along with p,p'-DDT, increased amplitude and had no effect on latency to onset of the ASR. In contrast, the Type II pyrethroids cypermethrin, cyfluthrin, and flucythrinate decreased amplitude and increased the latency to onset the ASR. Fenvalerate increased the amplitude, had no effect on latency, but unlike the other compounds tested, increased ASR sensitization. Fluvalinate had no effect on any measure of the ASR. The data provide further evidence of the differences between the in vivo effects of low dosages of Type I and II pyrethroids and extend the findings of our previous work to other representatives of the two classes of pyrethroids.